Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The eBook series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. The fourth volume of the series covers the following topics: -Aspirin administration -Adenosine receptor targeting for cardiovascular therapy -Drug treatment of patients with coronary stenting -Immunosuppressive drugs in heart transplantation -PCSK9 inhibition for lowering LDL-C levels.

Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. The fifth volume of the series covers the following topics: -The Lipid Hypothesis: From Resins to Proprotein Convertase Subtilisin/Kexin Type-9 Inhibitors -The Role of SGLT2i in the Prevention and Treatment of Heart Failure -Natural Products and Semi-Synthetic Compounds as Antithrombotics: A Review of the Last Ten Years (2009-2019) -Transient Receptor Potential Channels: Therapeutic Targets for Cardiometabolic Diseases? -Treatment of Raynaud’s Phenomenon -Traditional Medicine Based Cardiovascular Therapeutics -Cardiovascular Disease: A Systems Biology Approach

Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. Volume 6 covers the following topics: - Cardiovascular effects of ranolazine and the scope for translational research: a current review of literature - Rho/Rho kinase signaling pathway and disease: - Hibernation or transformation? Challenges in cardiovascular drug development - New approaches in P2Y12 receptor blocker drugs use - Pathophysiological links between diabetes and cardiovascular diseases: at the biochemical and molecular levels

Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest and the most important advances in Cardiovascular drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in cardiovascular drug design and discovery. Each volume is devoted to the major advances in cardiovascular drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Ethnopharmacology is one of the world’s fastest-growing scientific disciplines encompassing a diverse range of subjects. It links natural sciences research on medicinal, aromatic and toxic plants with socio-cultural studies and has often been associated with the development of new drugs. The Editors of Ethnopharmacology have assembled an international team of renowned contributors to provide a critical synthesis of the substantial body of new knowledge and evidence on the subject that has emerged over the past decade. Divided into three parts, the book begins with an overview of the subject including a brief history, ethnopharmacological methods, the role of intellectual property protection, key analytical approaches, the role of ethnopharmacology in primary/secondary education and links to biodiversity and ecological research. Part two looks at ethnopharmacological contributions to modern therapeutics across a range of conditions including CNS disorders, cancer, bone and joint health and parasitic diseases. The final part is devoted to regional perspectives covering all continents, providing a state-of-the –art assessment of the status of ethnopharmacological research globally. A comprehensive, critical synthesis of the latest developments in ethnopharmacology. Includes a section devoted to ethnopharmacological contributions to modern therapeutics across a range of conditions. Contributions are from leading international experts in the field. This timely book will prove invaluable for researchers and students across a range of subjects including ethnopharmacology, ethnobotany, medicinal plant research and natural products research. Ethnopharmacology- A Reader is part of the ULLA Series in Pharmaceutical Sciences www.ullapharmsci.org

Multiscale Cell-Biomaterials Interplay in Musculoskeletal Tissue Engineering and Regenerative Medicine addresses the key concepts involved in the interactions between cells and biomaterials in the musculoskeletal tissue engineering and regenerative medicine field. The updated developments and challenges of the mechanisms/mechanobiology and structure-function properties of those interactions, as well as emerging technologies underlying tissue-engineered scaffolding, are carefully discussed. Lastly, cell engineering and cell-based therapies, growth factors/drugs properties, vascularization, immunomodulation are also outlined. Given the large number of musculoskeletal disorders and related injuries that can affect muscles, bones and joints and lead to severe complications of the neuromuscular system, it is imperative to develop new treatment strategies to delay or repair associated diseases and to promote optimal long-term health. - Presents the fundamentals of the complex interplay of cells with biomaterials in musculoskeletal tissue engineering - Includes coverage of stem cells and cell-based therapies, in vitro and in vivo models, nanotechnology, bioprinting, computational modeling, regulatory and clinical translation, and much more - Written by global leaders in the field

With unprecedented interest in the power that the modern therapeutic armamentarium has to combat disease, the new edition of Drug Discovery and Development is an essential resource for anyone interested in understanding how drugs and other therapeutic interventions are discovered and developed, through to clinical research, registration, and market access. The text has been thoroughly updated, with new information on biopharmaceuticals and vaccines as well as clinical development and target identification. Drug discovery and development continues to evolve rapidly and this new edition reflects important changes in the landscape. Edited by industry experts Raymond Hill and Duncan Richards, this market-leading text is suitable for undergraduates and graduates undertaking degrees in pharmacy, pharmacology, toxicology, and clinical development through to those embarking on a career in the pharmaceutical industry. - Key stages of drug discovery and development - Chapters outline the contribution of individual disciplines to the overall process - Supplemented by specific chapters on different modalities - Includes coverage of Oligonucleotide therapies; cell and gene therapy - Now comes with online access on StudentConsult